Skip to main content

ADVERTISEMENT

Paul N Mudd Jr, PharmD, MBA

Review
05/05/2023
Qinghua Li
Molly W. Vaughan
Edith G. Walsh
Mark Hatem
Richard G. Stefanacci
Paul N Mudd Jr, PharmD, MBA
This literature review and advisory panel discussions highlight the need to increase education regarding anticholinergic burden for managing UI and lessening the adverse health outcomes assessed by NHQI quality measures.
This literature review and advisory panel discussions highlight the need to increase education regarding anticholinergic burden for managing UI and lessening the adverse health outcomes assessed by NHQI quality measures.
This literature review and...
05/05/2023
Annals of Long-Term Care
Practical Research
10/07/2022
Richard G Stefanacci, DO
John R. Horn, PharmD
Jason Yeaw, MPH
Drishti Shah, PhD
Adam Carrera, PharmD
Noelia Goti, BS
Stacie Holland, PharmD
Paul N Mudd Jr, PharmD, MBA
This study aims to describe the prevalence of CYP2D6 substrate use among LTC residents with OAB and among a subset of residents with OAB receiving mirabegron.
This study aims to describe the prevalence of CYP2D6 substrate use among LTC residents with OAB and among a subset of residents with OAB receiving mirabegron.
This study aims to describe the...
10/07/2022
Annals of Long-Term Care
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
Research Reports
05/18/2021
Richard G Stefanacci, DO
Jason Yeaw, MPH
Drishti Shah, PhD
Amy Kincaid, MA
Paul N Mudd Jr, PharmD, MBA
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and...
05/18/2021
Journal of Clinical Pathways